Application of preparation of pharmaceutical composition containing matrine and glycyrrhizic acid to treat psoriasis

A composition, the technology of glycyrrhizic acid, applied in the field of medicine, can solve the problems that patients are not suitable for use, and achieve the effect of remarkable effect and low toxic and side effects

Active Publication Date: 2018-06-08
施惠娟
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effective extract of Sophora flavescens or matrine has side effects such as diuresis and sodium excretion in clinical practice, so patients with excessive urine output should not use it.
Glycyrrhizic acid has anti-inflammatory, anti-allergic, anti-viral, and liver-protecting effects, but the steroid-like effect of glycyrrhizic acid, long-term oral administration of active ingredient extracts of licorice or glycyrrhizic acid and its derivatives will cause patients to have water and sodium retention, Serious adverse reactions such as hypertension and hypokalemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of preparation of pharmaceutical composition containing matrine and glycyrrhizic acid to treat psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Comparison of acute toxic effects of oxymatrine, glycyrrhizic acid and their compositions on mice

[0023] Kunming mice were randomly divided into a normal control group and a test drug group, with ten mice in each group, half male and half male. In addition to the normal control group, the test drug group was injected intraperitoneally (ip) with a large dose of oxymatrine, glycyrrhizin and the combination of the two components once, and the animals were observed continuously for 7 days, and the death time and number of animals were recorded.

[0024] The results showed that when the dose of oxymatrine was 950mg / kg, it had great toxicity, and 9 of the 10 mice died; when the dose of glycyrrhizin was 950mg / kg, 2 of the 10 mice died, while the oxidized Kushen minus: glycyrrhizin ratio 1:1 and combined dose of 950mg / kg and matrine: glycyrrhizin ratio of 2:1 and combined dosage of 950mg / kg, no animals died, oxidized matrine reduced: glycyrrhizin When the ratio of oxymatrine...

Embodiment 2

[0029] Observation on the curative effect of compound glycyrrhizin combined with oxymatrine in the treatment of psoriasis

[0030] 1 Materials and methods

[0031] 1.1 Clinical data 40 patients with psoriasis who were clinically diagnosed as psoriasis vulgaris, 20 males and 20 females, aged 24-58 years, had never received anti-psoriasis systemic treatment within one month, and had no photosensitivity disease , no serious visceral diseases such as liver and kidney dysfunction, no history of active tuberculosis, hypertension, diabetes, cataract, and pregnant and lactating women were excluded. The patients were randomly divided into four groups: oxymatrine treatment group (group A), compound glycyrrhizin treatment group (group B), oxymatrine combined with compound glycyrrhizin treatment group (group C), and control group (group D). group), ten cases in each group, half male and half male. There was no statistical difference among the four groups in terms of age, gender, and dis...

Embodiment 3

[0043] Oxymatrine 200mg

[0044] Diammonium Glycyrrhizinate 150mg

[0045] NaCl 0.9g

[0046] Appropriate amount of water for injection

[0047] 100ml each

[0048] Take NaCl, stir and dissolve with water for injection, then add oxymatrine and diammonium glycyrrhizinate respectively, dissolve completely while continuing to stir, add water for injection to the total amount, filter until clear, seal in a pot, and sterilize to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed are a pharmaceutical composition comprising kushenin and glycyrrhizic acid or derivatives thereof and the use of the composition in preparing a drug for preventing and treating psoriasis, wherein the weight ratio of the kushenin or a derivative thereof to the glycyrrhizic acid or a derivative thereof is 10:1-1:10.

Description

technical field [0001] The invention belongs to the field of medicine and relates to the application of a pharmaceutical composition in the preparation of prevention and treatment of psoriasis. The pharmaceutical composition contains matrine (oxymatrine, matrine, isomatrine) and glycyrrhizic acid or a pharmaceutically acceptable form of the two or derivatives of the two and the composition containing these The medicine box also includes glycyrrhizic acid matrine salt and glycyrrhizic acid matrine salt. Background technique [0002] Psoriasis is common disease of dermatology, frequently-occurring disease, still does not have the ideal medicine for the treatment of this disease at present. The etiology and pathogenesis of psoriasis are still unclear, but it is generally believed that psoriasis is a polygenic genetic disease that interacts with multiple factors, and finally causes keratinocytes to proliferate through a common immune-mediated pathway. Psoriasis is generally be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P17/06A61K31/4375
CPCA61K9/0019A61K9/2054A61K9/2059A61K31/353A61K31/704A61P17/06A61K2300/00
Inventor 施惠娟
Owner 施惠娟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap